Nuvectis Pharma (NVCT) Free Cash Flow (2021 - 2026)
Nuvectis Pharma (NVCT) posted Free Cash Flow of -$6.5 million for Q1 2026, down 63.84% sequentially from -$4.0 million in Q4 2025, and down 55.99% YoY from -$14.8 million in Q1 2025.
Nuvectis Pharma (NVCT) Free Cash Flow (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Free Cash Flow for 6 years, with the latest figure at -$6.5 million in Q1 2026.
- Quarterly Free Cash Flow fell 55.99% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.3 million (down 52.08% YoY) and the FY2025 annual result came in at -$16.0 million, down 30.72% from the prior year.
- Free Cash Flow slipped to -$6.5 million in Q1 2026 per NVCT's latest filing, from -$4.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$2.4 million in Q3 2024 and troughed at -$6.5 million in Q1 2026.
- A 5-year average of -$3.8 million and a median of -$3.8 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 229.52% in 2022, then soared 35.97% in 2024.
- Over 5 years, Free Cash Flow stood at -$3.5 million in 2022, then declined by 9.5% to -$3.8 million in 2023, then surged by 35.97% to -$2.5 million in 2024, then sank by 61.22% to -$4.0 million in 2025, then tumbled by 63.84% to -$6.5 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$6.5 million, -$4.0 million, and -$4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -4.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.53 Mn |
| Jun 30, 2026 | -4.53 Mn |
| Mar 31, 2026 | -6.51 Mn |
| Mar 31, 2026 | -6.51 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Dec 31, 2025 | -3.97 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Sep 30, 2025 | -4.49 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Mar 31, 2025 | -4.17 Mn |
| Mar 31, 2025 | -4.17 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Dec 31, 2024 | -2.47 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Mar 31, 2024 | -4.36 Mn |